AKT1 and cancer: IGF-1 receptor (IGF-1R) inhibitors prevent binding of IGF-1 to IGF1R and subsequently inhibit down stream signaling, including PI3K/Akt pathway, exerting antitumor activity and being potential targets for cancer treatment (Pollard and Daniel, 2019).